Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Paul_J._Hastings
|
| gptkbp:clinicalTrialPhase |
NKX019 for B-cell malignancies
NKX101 for acute myeloid leukemia (AML) |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:NKX019
gptkb:NKX101 |
| gptkbp:focusesOn |
gene therapy
natural killer (NK) cell therapies |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:James_Trager
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nkarta Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
off-the-shelf cell therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:NKTX
|
| gptkbp:website |
https://nkartatx.com/
|
| gptkbp:bfsParent |
gptkb:Samsara_BioCapital
|
| gptkbp:bfsLayer |
6
|